SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Biotechs >

Titan Pharmaceuticals Inc. (TTNPD)

Add TTNPD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator interstate, TRUTH, matthewverymuch, Ppower
Search This Board:
Last Post: 10/10/2015 6:45:04 AM - Followers: 159 - Board type: Free - Posts Today: 1



Probuphine®-This study is enrolling participants by invitation only.

Click For Link To

*November 20, 2014 -  the study is 100% enrolled. 
   * First patients enrolled on Jul 21, 2014 *                                  * DrKate Glassman-Beebe- Executive Vice President and Chief Development Officer-Titan Pharmaceuticals

Click For Link 


Braeburn Pharmaceuticals Identifier:
Information provided by (Responsible Party):
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals

Probuphine Graphic




Continuous Drug Delivery Technology


The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.


Fanapt® (iloperidone)


Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.

Company Overview

Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.


Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.


The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] quotations system. For further information please contact


Management Team

Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.


Board of Directors



Strategic Alliances

In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.


Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TTNP News: Statement of Changes in Beneficial Ownership (4) 10/01/2015 04:57:11 PM
TTNP News: Current Report Filing (8-k) 09/28/2015 03:03:45 PM
TTNP News: Current Report Filing (8-k) 09/28/2015 08:22:27 AM
TTNP News: Statement of Changes in Beneficial Ownership (4) 09/16/2015 06:49:15 PM
TTNP News: Current Report Filing (8-k) 09/09/2015 06:03:09 AM
News News Alert: Current Report Filing (8-k) 10/09/2015 12:08:05 PM
#5431  Sticky Note From brae's website... matthewverymuch 06/08/15 08:17:08 AM
#6220   Ah yes.... TRUTH 10/10/15 06:45:04 AM
#6219   Here is the sick part about it TRUTH, Rentier 10/09/15 06:47:54 PM
#6218   Nite ask got ran over hard TRUTH 10/09/15 04:36:30 PM
#6217   Awesome close at $4.50. Nite ask got AntiMarketMaker 10/09/15 04:03:08 PM
#6216   Epipens are now $450+ about year and half TRUTH 10/09/15 01:42:54 PM
#6215   If that is true that is a steal Rentier 10/09/15 01:31:07 PM
#6214   Epipens are now $450+ about year and half Rentier 10/09/15 01:30:13 PM
#6213   That seems like a good thing. On the NASDAQ Jkings 10/09/15 12:45:03 PM
#6212   So is thst 2 rods per 6 month turks 10/09/15 10:31:03 AM
#6211   I've never seen the company discuss it, but Doctor Detroit 10/09/15 09:49:10 AM
#6210   With all the media talk of overpricing prescription TRUTH 10/08/15 11:38:37 PM
#6209   Ttuth,what would you estimate be doesn't have turks 10/08/15 11:35:42 PM
#6208   Would anyone know or have any idea for pricing TRUTH 10/08/15 11:21:21 PM
#6207   Would anyone know or have any idea for turks 10/08/15 10:38:13 PM
#6206   Percentage of gain/loss and cost basis should now TRUTH 10/08/15 09:51:33 PM
#6205   I liked the tick up in volume today... TRUTH 10/08/15 09:44:19 PM
#6204   I liked the tick up in volume today.....this Chia 10/08/15 09:02:48 PM
#6203   I like your thinking! Good luck to us! Conrado4 10/08/15 11:50:39 AM
#6202   Imo only,you have to be a absolute turks 10/08/15 11:45:35 AM
#6201   Section 3(a)(9) of the Securities Act provides an TRUTH 10/08/15 10:45:29 AM
#6200   So are they basically cashing out the warrants interstate 10/08/15 10:19:40 AM
#6199   Fantastic news! Conrado4 10/08/15 09:50:12 AM
#6198   I am curious to see how the actual TRUTH 10/08/15 09:49:07 AM
#6197   Patience mostly pays - have been waiting for Klinsmann 10/08/15 09:45:32 AM
#6196   really thought that this PR would bring some TRUTH 10/08/15 09:44:17 AM
#6195   On the sidelines so far - really thought Klinsmann 10/08/15 09:38:46 AM
#6193   Titan Pharmaceuticals Announces Uplisting To NASDAQ TRUTH 10/08/15 08:55:17 AM
#6191   From Titan IR: BillCat 10/07/15 11:41:12 PM
#6190   That pr has nothing to do with today. matthewverymuch 10/07/15 10:35:47 PM
#6189   And if someone can decipher this one, please ekmey 10/07/15 10:31:55 PM
#6188   Wrong PR, that was from last year. ekmey 10/07/15 10:30:25 PM
#6187   Titan release a pr at 4:50pm today,you'll see turks 10/07/15 09:20:18 PM
#6177 matthewverymuch 10/07/15 12:30:50 PM
#6176   Read the 3rd paragraph. Read the date. matthewverymuch 10/07/15 12:28:31 PM
#6175   NOPE. 52 week high was June 8th... interstate 10/07/15 12:20:54 PM
#6174   No. You are mistaken. When shares were last matthewverymuch 10/07/15 12:10:09 PM
#6173   I know Braeburn is in charge of marketing... interstate 10/07/15 12:07:06 PM
#6172   WRONG... The R/S was announced after the run interstate 10/07/15 12:05:37 PM
#6171   This is one of the reasons I own mentalist 10/07/15 11:35:56 AM
#6170   I'll complain! stock price was capped at .98 matthewverymuch 10/07/15 11:22:06 AM
#6169   Post Approval=Braeburn Buys TTNP Doctor Detroit 10/07/15 11:22:00 AM
#6168   I hope no one is complaining now about interstate 10/07/15 09:53:09 AM
#6167   8k Out updated corporate presentation. mentalist 10/07/15 09:51:37 AM
#6166   This too shall pass.....this attack on all biotech Chia 10/06/15 10:36:02 PM
#6165   Drug Price Worries Derail Biotech Stocks…Again TRUTH 10/06/15 02:47:26 PM
#6164   Ibb getting smoked...wsj article on drug prices or something matthewverymuch 10/06/15 02:40:38 PM
#6163   Good info.... TRUTH 10/06/15 02:08:02 PM
#6162   Some good info here on TTNP from zacks. mentalist 10/06/15 09:55:06 AM
#6161   Stock hit high of $2.50 right before got Rentier 10/05/15 11:23:43 PM
#6160   I would say more like $12 or $13. Rentier 10/05/15 11:22:36 PM